Trending...
- North American Specialty Laminations ("NASL") Taps Industry Veteran Eric Spence to Lead National Business Development and Marketing Efforts
- PAN AMERICA 1250 MIVV proposes it with SPEED EDGE
- Yida Gao, Shima Capital Recognized for Prolific Deal Activity
MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil. as Chief Scientific Officer (CSO). In this newly created role, Dr. Gough will spearhead the expansion of Nimble's internal drug discovery capabilities that will enable further development of its own pipeline of proprietary therapeutics and drive Nimble towards becoming a fully integrated biotechnology company.
Dr. Gough has more than 25 years of experience in discovery research, both in academic settings as well as in the life sciences industry, and a track record of success in drug discovery and development, driving research programs into clinical study by building and leading high-performance teams. Prior to joining Nimble, Pete served as the CSO for Inzen Therapeutics, a Flagship company pioneering the newly discovered science of Thanokine Biology. At Inzen, he helped advance the company from seed stage to a successful Series B through the development of their pipeline of potentially transformational Immuno-Oncology therapeutics. Previously, Pete spent 15 years at GSK in roles of increasing responsibility. He served as Head of the Hepatitis B Virus Discovery Performance Unit (DPU) where he led GSK's efforts to develop a functional cure for HBV including proof of concept studies for bepirovirsen. He also served as Head of the Host Defense DPU, and prior to that was Head of Biology and DMPK in the Pattern Recognition Receptor DPU. Pete led, and oversaw, the discovery and development of a number of clinical assets across multiple therapeutic areas including RIP1 kinase inhibitor GSK2982772 and STING agonist GSK3745417.
More on Wisconsin Eagle
"We're excited to welcome Pete to our management team at Nimble," said Jigar Patel, PhD, Founder and CEO of Nimble Therapeutics. "Since our formation in 2019, Nimble has worked diligently to optimize and validate our peptide discovery platform. Pete brings invaluable experience in drug discovery and development across multiple therapeutic areas that will enable Nimble to deliver on the promise of peptide therapeutics through progressing and expanding our own internal pipeline."
"Nimble has built the industry leading platform for discovering peptide therapeutics that solves for the challenges that everyone else in the field is struggling with," said Dr. Gough. "I'm very excited to be part of the team and to help realize the truly transformative nature of the Nimble platform by advancing novel medicines into the clinic."
Earlier in his career, Pete was a Research Assistant Professor in the Department of Pathology at the University of Washington. He received his D. Phil. and M. A. from the University of Oxford. Pete has authored/co-authored over 100 scientific papers in peer-reviewed journals and has been an invited speaker at numerous academic institutions and scientific conferences.
About Nimble Therapeutics
Nimble is a biotechnology company dedicated to delivering on the promise of peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful analytics to efficiently and intelligently discover and develop next generation peptide therapeutics. Nimble has extensively validated its platform to identify highly biologically active compounds for multiple programs, spanning a wide variety of therapeutic target classes.
More on Wisconsin Eagle
Connect with us on LinkedIn at www.linkedin.com/company/nimble-therapeutics or visit our website at www.nimbletherapeutics.com to learn more.
Contacts
Nimble Therapeutics, Inc.
Brad Garcia, PhD
Vice President, Corporate Development
info@nimbletherapeutics.com
Dr. Gough has more than 25 years of experience in discovery research, both in academic settings as well as in the life sciences industry, and a track record of success in drug discovery and development, driving research programs into clinical study by building and leading high-performance teams. Prior to joining Nimble, Pete served as the CSO for Inzen Therapeutics, a Flagship company pioneering the newly discovered science of Thanokine Biology. At Inzen, he helped advance the company from seed stage to a successful Series B through the development of their pipeline of potentially transformational Immuno-Oncology therapeutics. Previously, Pete spent 15 years at GSK in roles of increasing responsibility. He served as Head of the Hepatitis B Virus Discovery Performance Unit (DPU) where he led GSK's efforts to develop a functional cure for HBV including proof of concept studies for bepirovirsen. He also served as Head of the Host Defense DPU, and prior to that was Head of Biology and DMPK in the Pattern Recognition Receptor DPU. Pete led, and oversaw, the discovery and development of a number of clinical assets across multiple therapeutic areas including RIP1 kinase inhibitor GSK2982772 and STING agonist GSK3745417.
More on Wisconsin Eagle
- Yida Gao and Shima Capital Celebrate Portfolio Company's Successful NFT Sellout
- "Murdaugh Murders Podcast" Launches Spinoff "Cup of Justice" and Skyrockets to Apple's #1 Podcast
- CPAC 2023 Congressional Candidate Forum Meet and Greet March 2nd at the historic University Club in DC
- IoT Observatory to host Plenary Session at 2023 InsurTech Hartford Symposium
- Eliza Neals "Candy Store" new spring single out February 14th Valentines Day 2023!
"We're excited to welcome Pete to our management team at Nimble," said Jigar Patel, PhD, Founder and CEO of Nimble Therapeutics. "Since our formation in 2019, Nimble has worked diligently to optimize and validate our peptide discovery platform. Pete brings invaluable experience in drug discovery and development across multiple therapeutic areas that will enable Nimble to deliver on the promise of peptide therapeutics through progressing and expanding our own internal pipeline."
"Nimble has built the industry leading platform for discovering peptide therapeutics that solves for the challenges that everyone else in the field is struggling with," said Dr. Gough. "I'm very excited to be part of the team and to help realize the truly transformative nature of the Nimble platform by advancing novel medicines into the clinic."
Earlier in his career, Pete was a Research Assistant Professor in the Department of Pathology at the University of Washington. He received his D. Phil. and M. A. from the University of Oxford. Pete has authored/co-authored over 100 scientific papers in peer-reviewed journals and has been an invited speaker at numerous academic institutions and scientific conferences.
About Nimble Therapeutics
Nimble is a biotechnology company dedicated to delivering on the promise of peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful analytics to efficiently and intelligently discover and develop next generation peptide therapeutics. Nimble has extensively validated its platform to identify highly biologically active compounds for multiple programs, spanning a wide variety of therapeutic target classes.
More on Wisconsin Eagle
- The Case For Bonds As Part Of A Portfolio
- Madison: Snow Emergency Continues Tonight; Overnight Alternate Side Parking Rules in Effect Citywide
- Cardinal Analytics Launches on the Bloomberg App Portal
- 24th Annual Super Bowl Soulful Celebration Returns On Feb. 8 With Patti LaBelle, Israel Houghton & The Players Choir, Honoring NFL QB Jalen Hurts
- Orbex to Exhibit as Diamond Sponsor at the Fintech & Crypto Summit Bahrain, 2023
Connect with us on LinkedIn at www.linkedin.com/company/nimble-therapeutics or visit our website at www.nimbletherapeutics.com to learn more.
Contacts
Nimble Therapeutics, Inc.
Brad Garcia, PhD
Vice President, Corporate Development
info@nimbletherapeutics.com
Filed Under: Business
0 Comments
Latest on Wisconsin Eagle
- Flawless Torres ft. Diamonique x Sean Kingston Releases "Lets Go" on 1/27/23!
- We're In Paris Is Sidow Sobrino's Newly Released Song and Video
- Abusive Russian to face Pro Wrestling Legend!
- Jim Wilson, Top Notch Realtor in waterfront and beach properties in Redington, Redington Shores, and North Redington Beach, FLorida
- Multi #1 International Best-Selling Author Jennifer S. Wilkov Announces the 2023 April Speak Up Women Conference and Call For Speakers
- Church Mutual® Survey Finds U.S. Economic Challenges Not Expected to Derail 2023 Charitable Giving
- Cascade Asset Management Releases its 9th Annual IT Asset Disposition Benchmarking Report
- Mayville Engineering Company Announces Appointment of Sean Leuba as Senior Vice President, Corporate Development and General Counsel
- Electives, Inc. doubles its live learning library to include more than 450 classes
- Bottled Ambrosia Launches to Provide Access to the Best European Organic Baby Formulas for US and Canadian Families
- Madison: New hours begin Feb. 1
- Call for Artists: Our Town Everywhere Self-Portraits Project with The Bubbler at Madison Public Library
- Madison: Several offices on the ballot this spring require a primary election on February 21.
- Madison: Next John Nolen Drive Public Information Meeting: Feb. 23
- Yida Gao, Shima Capital Recognized for Prolific Deal Activity
- PAN AMERICA 1250 MIVV proposes it with SPEED EDGE
- North American Specialty Laminations ("NASL") Taps Industry Veteran Eric Spence to Lead National Business Development and Marketing Efforts
- Southern California Real Estate Agent Promotes Homes To MORE Buyers For MORE Money
- Can Massage Therapy Be an Effective Treatment for Long Haul COVID?
- Madison: MPD hosts chili cook-off to benefit families of fallen officers